Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/3010% above fair value
$957.76+5.36 (+0.56%)
Close on Nov 17, 2026Market cap $99.08BP/E 21.2Yield –
Regeneron Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Regeneron Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was $4.85B, down 4.4% year over year. For fiscal 2025 it was $4.98B, up 12.6% from the year before. Over ten years it grew 14.1% a year on average. The highest annual figure on record is $7.08B in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.98B | +12.6% |
| FY2024 | Dec 31, 2024 | $4.42B | -3.8% |
| FY2023 | Dec 31, 2023 | $4.59B | -8.4% |
| FY2022 | Dec 31, 2022 | $5.01B | -29.2% |
| FY2021 | Dec 31, 2021 | $7.08B | +170.5% |
| FY2020 | Dec 31, 2020 | $2.62B | +7.7% |
| FY2019 | Dec 31, 2019 | $2.43B | +10.7% |
| FY2018 | Dec 31, 2018 | $2.20B | +67.9% |
| FY2017 | Dec 31, 2017 | $1.31B | -12.0% |
| FY2016 | Dec 31, 2016 | $1.49B | +11.7% |
| FY2015 | Dec 31, 2015 | $1.33B | +76.9% |
| FY2014 | Dec 31, 2014 | $752.44M | +27.8% |
| FY2013 | Dec 31, 2013 | $588.60M | – |
| FY2012 | Dec 31, 2012 | -$74.62M | – |
| FY2011 | Dec 31, 2011 | -$141.68M | -242.8% |
| FY2010 | Dec 31, 2010 | $99.22M | – |
| FY2009 | Dec 31, 2009 | -$69.94M | – |
| FY2008 | Dec 31, 2008 | -$89.09M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.78B | +10.2% |
| Q2 FY2026 | Jun 30, 2026 | $813.00M | -29.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.08B | +3.2% |
| Q4 FY2025 | Dec 31, 2025 | $1.17B | -7.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.62B | +25.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.14B | +223.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.05B | -30.9% |
| Q4 FY2024 | Dec 31, 2024 | $1.26B | +15.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.29B | +15.9% |
| Q2 FY2024 | Jun 30, 2024 | $354.00M | -65.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.51B | +10.6% |
| Q4 FY2023 | Dec 31, 2023 | $1.09B | -36.6% |
| Q3 FY2023 | Sep 30, 2023 | $1.11B | +77.2% |
| Q2 FY2023 | Jun 30, 2023 | $1.02B | +81.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.37B | -34.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.72B | -27.5% |
| Q3 FY2022 | Sep 30, 2022 | $628.90M | -81.6% |
| Q2 FY2022 | Jun 30, 2022 | $564.40M | -9.9% |
| Q1 FY2022 | Mar 31, 2022 | $2.10B | +214.4% |
| Q4 FY2021 | Dec 31, 2021 | $2.37B | +92.7% |
| Q3 FY2021 | Sep 30, 2021 | $3.41B | – |
| Q2 FY2021 | Jun 30, 2021 | $626.70M | -33.6% |
| Q1 FY2021 | Mar 31, 2021 | $668.50M | -4.2% |
| Q4 FY2020 | Dec 31, 2020 | $1.23B | +56.3% |
| Q3 FY2020 | Sep 30, 2020 | -$254.30M | -145.6% |
| Q2 FY2020 | Jun 30, 2020 | $943.40M | +401.0% |
| Q1 FY2020 | Mar 31, 2020 | $698.00M | -22.2% |
| Q4 FY2019 | Dec 31, 2019 | $787.40M | +8.0% |
| Q3 FY2019 | Sep 30, 2019 | $557.30M | +23.1% |
| Q2 FY2019 | Jun 30, 2019 | $188.30M | -52.3% |
| Q1 FY2019 | Mar 31, 2019 | $897.00M | +45.0% |
| Q4 FY2018 | Dec 31, 2018 | $728.80M | +28.6% |
| Q3 FY2018 | Sep 30, 2018 | $452.90M | +9.2% |
| Q2 FY2018 | Jun 30, 2018 | $394.60M | – |
| Q1 FY2018 | Mar 31, 2018 | $618.80M | +73.9% |
| Q4 FY2017 | Dec 31, 2017 | $566.94M | +45.2% |
| Q3 FY2017 | Sep 30, 2017 | $414.83M | – |
| Q2 FY2017 | Jun 30, 2017 | -$30.57M | – |
| Q1 FY2017 | Mar 31, 2017 | $355.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $390.38M | – |
See a number that looks wrong?